Info onlyNot investment advice. GSE prices are end-of-day; FX and news refresh live.How we source
N
Nkosuo
GSE · Closed · Weekend
Live
GSE-CI14,873.11— 0.00%GSE-FSI1,745.04▲ +2.81%MTNGHGH₵2.45▲ +1.66%GCBGH₵6.85▼ -0.72%EGHGH₵8.25▲ +1.85%SCBGH₵24.50▲ +1.66%CALGH₵0.38▼ -7.32%SOGEGHGH₵1.35▲ +1.50%ACCESSGH₵4.10▲ +1.23%RBGHGH₵0.72▲ +2.86%EGLGH₵3.20▲ +2.56%SICGH₵0.44▲ +2.33%FMLGH₵5.20▲ +0.39%UNILGH₵14.50▲ +2.11%GGBLGH₵3.10▲ +1.64%PZCGH₵0.68▲ +1.49%GOILGH₵1.55▲ +1.97%TOTALGH₵9.40▲ +1.08%TLWGH₵16.80▼ -1.75%BOPPGH₵22.50▲ +0.90%AYRTNGH₵0.11— 0.00%MACGH₵5.40— 0.00%ADBGH₵5.06— 0.00%AGAGH₵37.00— 0.00%ALWGH₵0.10— 0.00%ASGGH₵8.87— 0.00%CLYDGH₵0.03— 0.00%CMLTGH₵0.10— 0.00%CPCGH₵0.02— 0.00%DASPHARMAGH₵0.40— 0.00%DIGICUTGH₵0.09— 0.00%ETIGH₵0.15— 0.00%HORDSGH₵0.10— 0.00%IILGH₵0.04— 0.00%MMHGH₵0.11— 0.00%GSE-CI14,873.11— 0.00%GSE-FSI1,745.04▲ +2.81%MTNGHGH₵2.45▲ +1.66%GCBGH₵6.85▼ -0.72%EGHGH₵8.25▲ +1.85%SCBGH₵24.50▲ +1.66%CALGH₵0.38▼ -7.32%SOGEGHGH₵1.35▲ +1.50%ACCESSGH₵4.10▲ +1.23%RBGHGH₵0.72▲ +2.86%EGLGH₵3.20▲ +2.56%SICGH₵0.44▲ +2.33%FMLGH₵5.20▲ +0.39%UNILGH₵14.50▲ +2.11%GGBLGH₵3.10▲ +1.64%PZCGH₵0.68▲ +1.49%GOILGH₵1.55▲ +1.97%TOTALGH₵9.40▲ +1.08%TLWGH₵16.80▼ -1.75%BOPPGH₵22.50▲ +0.90%AYRTNGH₵0.11— 0.00%MACGH₵5.40— 0.00%ADBGH₵5.06— 0.00%AGAGH₵37.00— 0.00%ALWGH₵0.10— 0.00%ASGGH₵8.87— 0.00%CLYDGH₵0.03— 0.00%CMLTGH₵0.10— 0.00%CPCGH₵0.02— 0.00%DASPHARMAGH₵0.40— 0.00%DIGICUTGH₵0.09— 0.00%ETIGH₵0.15— 0.00%HORDSGH₵0.10— 0.00%IILGH₵0.04— 0.00%MMHGH₵0.11— 0.00%

Healthcare

Ayrton Drug and a handful of pharmaceutical listings. Revenue tracks NHIS reimbursement cycles and private-pay growth.

Market cap
GH₵139.85M
0.1% of listed market
Average 1y return
—
equal-weighted across 4 names
Average dividend yield
—
trailing, equal-weighted
Liquidity
1.3/10
average grade

Industries within healthcare

Pharmaceuticals

4 names

All 4 listed names in healthcare

TickerIndustryPriceDay %McapYieldLiquidity
DASPHARMA
Dannex Ayrton Starwin
PharmaceuticalsGH₵0.400.00%90M—E
AYRTN
Ayrton Drug Manufacturing
PharmaceuticalsGH₵0.110.00%28M—E
HORDS
Hords
PharmaceuticalsGH₵0.100.00%11.5M—E
IIL
Intravenous Infusions
PharmaceuticalsGH₵0.040.00%10.4M—E

What to watch

NHIS payment arrears to providers, raw-material import costs (API prices in INR/CNY), and generic drug policy.

Policy-maker & analyst lens

Healthcare listings are a clean test of NHIS solvency — when provider arrears climb, it shows up in working-capital strain at pharmaceutical distributors before it hits patients at the counter.

Sector analysis is editorial and data is end-of-day. Not investment advice. See all sectors · macro dashboard · global economic context.